National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Canagliflozin (Invokana®) is indicated for the treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin

Rapid Review

Commenced Completed Outcome
25/11/2013 02/12/2013 Full HTA Recommended


Pharmacoeconomic Evaluation

Commenced Completed Outcome
17/04/2014  29/08/2014 Reimbursement not recommended under the submitted pricing structure.


December 2014

The HSE has approved reimbursement following confidential price negotiations.